Telomir Pharmaceuticals, Inc. TELO 深 沪
已收盘 09-25 16:00:00 美东时间
1.23
+0.020
+1.65%
华盛通- 最 高1.23
- 今 开1.22
- 成交量 5.60万股
- 最 低 1.20
- 昨 收 1.21
- 总市值 8459.32万
- 52周最高 2.091
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 0.8885
- 委 比 -99.47%
- 总股本 6877.50万
- 历史最高 20.72
- 量 比 0.40
- 振 幅 2.48%
- 历史最低 0.8885
- 每 手 1
- 风险率 0.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Telomir Announces New Research Findings From Ohio State University College Of Veterinary Medicine Showing Telomir-Zn Produces Inhibition Of Cell Growth Across Human And Canine Osteosarcoma Models
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn...
09-14 20:01
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Telomir Pharmaceuticals announced new research findings showing that Telomir-Zn inhibits cell growth in both human and canine osteosarcoma models, supporting its potential for treating osteosarcoma in both species. The study, conducted at Ohio State University's College of Veterinary Medicine, demonstrated consistent anti-tumor activity across human and canine cell lines, suggesting the compound could offer a therapeutic opportunity for veterinar...
09-14 12:00
Telomir Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Andriy Mushak as the Fractional Chief Financial
06-09 05:03
Telomir Pharma Announces Peer-Reviewed Publication Of Preclinical Data Showing Telomir-Zn Produced Dose-Dependent Survival Improvement Across Multiple Endpoints In Wilson's Disease Model
Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease
05-20 20:04
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study
Telomir wins FDA IND clearance for Telomir-Zn in TNBC, enabling a Phase 1/2 study targeting epigenetic cancer pathways.
04-30 19:46
Telomir Pharmaceuticals Submits Investigational New Drug Application To FDA To Treat Advanced And Metastatic Triple-Negative Breast Cancer
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today
03-31 20:23
Telomir Pharmaceuticals Announces New Data Supporting Telomir-Zn's Mechanism In Cancer And Aging, Plans Submission For Investigational New Drug Application In Q1 2026
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms.
02-05 21:09
Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC
Telomir Pharmaceuticals, Inc. ( ($TELO) ) just unveiled an update. Telomir Phar...
01-05 21:39
Telomir Pharmaceuticals Results From Trial In Zebrafish Tumor Xenograft Animal Models Of Triple-Negative Breast Cancer Shows Reductions In Primary Tumor Growth, Spread Of Cancer Cells
Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced
01-05 21:07
